Cenegenics Atlanta

Long term improvement of quality of life during human growth hormone HGH replacement therapy in adults with HGH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H).

Rosilio M - J Clin Endocrinol Metab - 01-APR-2004; 89(4): 1684-93
NLM Citation ID:
15070931 (PubMed)
Full Source Title:
Journal of Clinical Endocrinology and Metabolism
Publication Type:
Journal Article
Author Affiliation:
Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285, USA. rosilio_myriam@lilly.com
Rosilio M; Blum WF; Edwards DJ; Shavrikova EP; Valle D; Lamberts SW; Erfurth EM; Webb SM; Ross RJ; Chihara K; Henrich G; Herschbach P; Attanasio AF
Questions on Life Satisfaction-Hypopituitarism (QLS-H) is a new quality-of-life (QoL) questionnaire developed for adults with hypopituitarism. To determine the effects of long-term HGH treatment on QoL, we evaluated QLS-H Z-scores in 576 adult patients with HGH deficiency (GHD) enrolled in HypoCCS, an international observational study, using data from five countries in which comparative QLS-H data from the general population were available. Baseline QLS-H Z-scores were significantly lower in HGH-deficient patients than in the general population of the same age, gender, and nationality. Z-scores were also significantly lower in female patients vs. males (P = 0.006) and in adult-onset vs. childhood-onset HGHD (P = 0.002). Multivariate analysis associated female gender, multiple pituitary hormone deficiencies, low serum IGF-I values (<75 micro g/liter), and concomitant antidepressant medication with low baseline Z-scores. QLS-H Z-scores increased from -1.02 +/- 1.43 (SD) at baseline to -0.25 +/- 1.34 (SD) after 1 yr of HGH treatment (P < 0.001) and were no longer significantly different from the general population after 4 yr of treatment. There was no correlation between change in Z-score and HGH dose or changes in IGF-I and IGF binding protein-3 during treatment. This study demonstrates that 1) improvements in QoL, as measured by the QLS-H, are maintained during long-term HGH replacement therapy of adults with HGHD, and 2) the QLS-H is a useful tool for evaluating QoL in hypopituitary patients treated in clinical practice. The authors suggest that evaluation of QoL should be a part of the routine clinical management of adult HGH-deficient patients, complementing the measurement of surrogate biological markers or other clinical end points.
Major Subjects:

Additional Subjects:

Chemical Compound Name:
12629-01-5(Human Growth Hormone)

| Site Map | Links & Resources | Contact Us | ©2004 - 2005 Anti-Aging & Weight Loss Medicine, LLC - Disclaimer and Copyright